AdAlta reports favourable patient tolerability after third dose in AD-214 extension study

AdAlta (ASX:1AD), a clinical-stage company developing novel protein and cell therapeutic products from its i-body platform, has announced that all healthy volunteers in its AD-214 Phase 1 extension study have now successfully received three doses. …